Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R01 Clinical Trial Not Allowed)
ID: 336394Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/336394

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-22-061.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer" (R01 Clinical Trial Not Allowed), aimed at supporting research into the interactions between the human microbiome and anti-tumor immune responses. This initiative encourages applications that explore how specific microbes or their metabolites can influence immune behavior to prevent tumor formation, with a focus on identifying novel molecular targets for cancer prevention strategies. The funding opportunity is open to a wide range of eligible applicants, including various educational institutions and organizations, and projects must avoid clinical trials, have a maximum duration of five years, and demonstrate adequate preliminary data. Interested applicants should note that the submission deadline is January 7, 2025, and can find more information at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAR-22-061-Full-Announcement.html
    PAR-22-061.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has issued a Funding Opportunity Announcement (FOA) titled "Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer” (PAR-22-061). This announcement encourages applications that investigate the interactions between the human microbiome and anti-tumor immune responses, aiming to identify novel molecular targets for cancer prevention. Researchers are invited to explore how specific microbes or their metabolites can influence immune behavior to prevent tumor formation. The submission process for applications is outlined, with specified due dates and eligibility criteria, emphasizing compliance with NIH policies. Projects must avoid clinical trials, have a maximum duration of five years, and demonstrate adequate preliminary data. Importantly, the FOA aims to uncover mechanisms that enhance anti-tumor immunity through microbial interactions, linking research to potential clinical applications. Overall, the initiative reflects NIH's commitment to advancing cancer research through innovative approaches involving the human microbiome.
    Similar Opportunities
    Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer," aimed at supporting exploratory research into the human microbiome's role in anti-tumor immunity. This initiative seeks to elucidate the mechanisms by which specific microbes or their metabolites influence immune responses and inflammation related to tumor formation, with a focus on identifying novel molecular targets for cancer prevention strategies. Eligible applicants include a wide range of organizations, such as educational institutions, nonprofits, and tribal governments, with funding available up to $275,000 for two-year projects. Interested parties should submit their applications by January 7, 2025, and can find additional information at the NIH website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Microbial-based Cancer Imaging and Therapy - Bugs as Drugs" (R01 Clinical Trial Not Allowed), aimed at advancing research on the use of microorganisms for cancer treatment and diagnostics. This initiative invites grant applications that explore the interactions between bacteria, archaebacteria, bacteriophages, and tumors, focusing on their potential to enhance cancer imaging, therapeutics, and diagnostics, particularly for solid tumors. The program encourages multidisciplinary collaborations and aims to address current limitations in cancer therapies, with a significant emphasis on improving treatment outcomes in low-resource settings. Interested applicants can find more information and submit their proposals by May 7, 2025, and should direct inquiries to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Microbial-based Cancer Imaging and Therapy - Bugs as Drugs," aimed at exploring innovative strategies for cancer therapy and diagnostics utilizing microorganisms. This R21 grant supports exploratory projects that investigate the interactions between tumors and microorganisms, such as bacteria and viruses, with a focus on enhancing immune responses and developing new imaging technologies, particularly for solid tumors and oral cancers. The initiative seeks to address critical gaps in current cancer treatment modalities and encourages proposals that demonstrate innovative, multi-disciplinary approaches. Eligible applicants can request funding up to $275,000 over a two-year project period, with applications due by May 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-086.html.
    Co-infection and Cancer (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Co-infection and Cancer (R01 Clinical Trial Not Allowed)" aimed at enhancing the understanding of infection-related cancers, particularly the roles of co-infection in cancer development. This initiative encourages mechanistic and epidemiologic studies that explore how infections by multiple agents—both pathogenic and non-pathogenic—can influence cancer risk and progression, with a focus on known oncogenic agents, excluding HIV. Given the significant proportion of cancer cases linked to infectious agents, this research is crucial for developing novel prevention and treatment strategies. Interested applicants, including a variety of educational institutions and organizations, particularly those from underrepresented groups, must submit their applications by November 5, 2025, and can find further details and guidelines at the NIH website or contact NIH Grants Information at grantsinfo@nih.gov.
    Co-infection and Cancer (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Co-infection and Cancer (R21 Clinical Trial Not Allowed)" aimed at enhancing research on the mechanisms and epidemiology of co-infections in relation to cancer development. This grant seeks innovative proposals that investigate how co-infections, particularly those involving known oncogenic agents (excluding HIV), may influence carcinogenesis and contribute to cancer disparities among diverse populations. The maximum funding amount available for each application is $275,000 over a two-year period, with applications due by November 16, 2025. Eligible applicants include a wide range of institutions and organizations, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)." This initiative invites applications aimed at improving the utility of mammalian cancer models, including organoids and tumoroids, to better represent human biology and address translational deficiencies in existing models. The funding seeks to advance cancer research by fostering innovative approaches to validate these models and enhance their clinical relevance, ultimately aiming to improve patient outcomes. Eligible applicants can receive up to $499,000 per year for a maximum of five years, with applications due by September 7, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-281.html.
    Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Molecular Imaging of Inflammation in Cancer" funding opportunity, specifically under the R01 Clinical Trial Not Allowed grant mechanism. This initiative aims to support innovative research utilizing molecular imaging techniques to explore the interplay between inflammation and tumor behavior in vivo, encouraging collaborative efforts between cancer researchers and imaging scientists. The focus is on developing imaging probes and methodologies that can accurately monitor inflammatory processes in cancer, leveraging existing knowledge from both cancer biology and imaging technologies. Interested applicants must submit their proposals by January 7, 2025, and can find additional information and application details at the NIH grants website or contact the NIH OER Webmaster at grantsinfo@nih.gov for assistance.
    Understanding Mechanisms and Outcomes of Trained Immunity (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Understanding Mechanisms and Outcomes of Trained Immunity" through the R21 grant mechanism, aimed at advancing research into innate immune memory, known as trained immunity. This initiative seeks to enhance understanding of the mechanisms, biomarkers, and functional implications of trained immunity, particularly in relation to immune system development, vaccine efficacy, and various diseases, while explicitly prohibiting clinical trials. The grant provides a maximum funding amount of $275,000, with applications accepted starting May 16, 2024, and a closing date of January 7, 2027. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Enhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Enhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional)" aimed at advancing innovative research into precision probiotic interventions. This initiative seeks applications that will investigate person-specific factors influencing probiotic responses, such as microbiome composition, age, sex, genetic background, and lifestyle, to identify subgroups that may benefit from tailored probiotic treatments. The funding is crucial for addressing variability in human responses to probiotics and aims to enhance health outcomes through targeted interventions. Applicants can request up to $350,000 per year for a maximum of four years, with the application deadline set for June 2, 2027. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-239.html.
    Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research," aimed at advancing innovative research in biomimetic tissue-engineered technologies for cancer. This initiative seeks to support collaborative, multidisciplinary projects that integrate regenerative medicine, tissue engineering, and cancer biology to develop advanced in vitro and ex vivo models that accurately mimic human cancer pathophysiology. The funding opportunity is crucial for enhancing cancer research methodologies and understanding disease mechanisms, with a maximum budget of $400,000 per year and a project duration of up to five years. Interested applicants must submit their proposals electronically via Grants.gov by May 8, 2025, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.